News

latest corporate presentation

Latest Summary Corporate Presentation

November 2023

View Presentation
18 Oct 2023 Actinogen Latest Summary Corporate Presentation October 2023
06 Oct 2023 Actinogen Company Presentation: ACW CEO presents to Dementia Trials Australia conference
29 Sep 2023 Actinogen Company Presentation: ACW Clinical Scientist presents to the Asian Society Against Dementia congress
14 Sep 2023 Actinogen Video interview: [14.46 mins] Xanamem program update
31 Aug 2023 Media Webcast video recording: Actinogen neuroscience webinar
07 Jun 2023 PR Newswire Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer’s Disease Phase 2 trials at the BIO International Convention
31 May 2023 PR Newswire Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer’s Disease Phase 2 trials at the BIO International Convention
31 May 2023 Yahoo Finance Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer’s Disease Phase 2 trials at the BIO International Convention
24 May 2023 Actinogen Webcast video recording: Actinogen Clinical Trials Science Forum 2023
30 Mar 2023 PR Newswire Actinogen presents positive Phase 2a Xanamem data at AD/PD™ Alzheimer’s and Parkinson’s diseases conference
30 Mar 2023 Actinogen Oral presentation: CMO presentation at Alzheimer’s and Parkinson’s Disease Conference (AD/PD™) in Gothenburg, Sweden
01 Mar 2023 Biotech Daily Actinogen Appoints Nicki Vasquez Non-Executive Director
24 Feb 2023 Actinogen Company presentation: Spark Plus Biotech Conference in Singapore
01 Feb 2023 Biotech Daily Actinogen Appoints Dr Dana Hilt CMO
09 Jan 2023 Actinogen Company presentation: Sachs Neuroscience Innovation Forum and other meetings during the JP Morgan Healthcare Conference week
22 Dec 2022 Biotech Daily FDA Okays Actinogen 6-Months Xanamem Phase IIb Alzheimer’s Trial
22 Dec 2022 Seeking Alpha FDA agrees to Actinogen six-month Phase 2b Alzheimer’s Disease trial
22 Dec 2022 PR Newswire FDA agrees to Actinogen six-month Phase 2b Alzheimer’s Disease trial
22 Dec 2022 MarketWatch FDA agrees to Actinogen six-month Phase 2b Alzheimer’s Disease trial
22 Dec 2022 Yahoo FDA agrees to Actinogen six-month Phase 2b Alzheimer’s Disease trial
22 Dec 2022 The Market Herald Actinogen Medical (ASX:ACW) receives FDA approval for six-month phase 2b Alzheimer trial
22 Dec 2022 BioSpace FDA agrees to Actinogen six-month Phase 2b Alzheimer’s Disease trial
15 Dec 2022 Yahoo Finance Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial
15 Dec 2022 Daily Bulletin Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial
15 Dec 2022 BioPharma APAC Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial
14 Dec 2022 PR Newswire Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial
14 Dec 2022 BioSpace Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial
08 Dec 2022 Biotech Daily Actinogen Treats First Xanamem Depression Patient
03 Dec 2022 Actinogen Poster presentation: CTAD conference 2022
25 Nov 2022 Biotech Daily Dr Boreham’s Crucible: Actinogen Medical
16 Nov 2022 Actinogen Webcast video recording: AGM 16 Nov 2022 ACW Chair’s Address and CEO presentation
16 Nov 2022 Actinogen Company presentation: AGM 16 Nov 2022 ACW Chair’s Address and CEO presentation
09 Nov 2022 Bell Potter Webcast video recording: CEO presentation to Bell Potter Healthcare Conference 2022
09 Nov 2022 Actinogen Company presentation: CEO presentation to Bell Potter Healthcare Conference 2022
03 Nov 2022 SparkPlus Webinar video recording: CEO presentation at Spark Plus Healthcare Day
03 Nov 2022 Actinogen Company presentation: CEO presentation to Spark Plus Healthcare Day
24 Oct 2022 ShareCafe Webinar video recording: CEO presentation at ShareCafe “Hidden Gems”
21 Oct 2022 Yahoo Finance Actinogen Medical: re-initiation — Cognitive enhancer targeting key diseases
21 Oct 2022 Actinogen Company presentation: CEO presentation at ShareCafe “Hidden Gems”
19 Oct 2022 Stockhead Alzheimer’s drug no longer a moonshot as race heats up, ASX-listed Actinogen in the running
19 Oct 2022 FN Arena Australian Broker Call *Extra* Edition – Oct 19, 2022
12 Oct 2022 Outsourcing-Pharma.com “Significant Step Forward” for Actinogen’s Alzheimer’s treatment
11 Oct 2022 EIN Presswire Actinogen Medical (ACW) announces large Xanamem® therapeutic effect in early-stage Alzheimer’s Disease (AD) patients
11 Oct 2022 BioWorld Biomarker analysis yields clinical benefit for Actinogen’s Xanamem in Alzheimer’s disease
10 Oct 2022 Actinogen Webcast video recording: Alzheimer’s Disease biomarker study clinical results – Large clinical benefit on FDA-approved measurement of cognition and function in patients with Alzheimer’s Disease
10 Oct 2022 The Market Herald Actinogen Medical (ASX:ACW) finds positive results in phase 2A trial of Xanamem on Alzheimers
10 Oct 2022 BioSpace Clinical Catch-Up: Actinogen, Applied Therapeutics, BrainStorm, Immatics, and More
10 Oct 2022 Labiotech.eu Positive data indicates likely therapeutic effect of Alzheimer’s drug
10 Oct 2022 Biotech Daily Actinogen Xanamem Alzheimer’s Biomarker Effect
10 Oct 2022 The Motley Fool Why Actinogen, Core Lithium, Fortescue, and Galileo Mining shares are pushing higher
Load more

Back
to top